secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2026-09-03T12:15:14+00:00
Accession:  0001193125-26-381098
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo reports 93% clinical benefit rate with mipletamig triplet in TP53-mutated AML
--------------------------------------------------------------------------------

- Of 14 evaluable TP53-mutated frontline AML patients, 13 (93%) achieved clinical benefit; 11 (79%) achieved CR/CRi, including 9 CRs.
- 79% CR/CRi compares favorably to published 41% composite remission rate for venetoclax plus azacitidine in this population.
- RAINIER dose optimization trial expected to complete by year-end 2026; regulatory interaction planned for 1H27.
- Data include two patients from previously completed dose expansion trial; mipletamig combined with venetoclax and azacitidine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526381098/0001193125-26-381098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526381098/apvo-20260903.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-381098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer